Comparable stake leader
PERCEPTIVE ADVISORS LLC
SEC ownership of Opus Genetics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001228627.
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
50/50
Latest evidence
18 May 2026
- Public ticker
- IRD on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
PERCEPTIVE ADVISORS LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
PERCEPTIVE ADVISORS LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
18 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001228627
- Issuer location
- Durham, NC
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Opus Genetics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PERCEPTIVE ADVISORS LLC
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
50/50
Latest evidence
18 May 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: PERCEPTIVE ADVISORS LLC
Showing 1-8 of 50 holder rows.
Quick read
PERCEPTIVE ADVISORS LLC leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PERCEPTIVE ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
PERCEPTIVE ADVISORS LLC
10%
Caligan Partners LP
8.5%
Adage Capital Management, L.P.
8.5%
BALYASNY ASSET MANAGEMENT L.P.
7.2%
Nantahala Capital Management, LLC
6.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
Company
|
10%
|
$43,444,313
8,830,145 shares
|
+$8,147,476 | 31 Mar 2026 |
| Caligan Partners LP |
13D/G
13F
Company
|
8.5%
|
$29,889,138
6,075,028 shares
|
$0 | 31 Mar 2026 |
| Adage Capital Management, L.P. |
13D/G
|
8.5%
|
$29,666,493
6,029,775 shares
|
$0 | 31 Mar 2026 |
| BALYASNY ASSET MANAGEMENT L.P. |
13D/G
13F
Company
|
7.2%
|
$25,143,035
5,110,373 shares
|
$0 | 31 Mar 2026 |
| Nantahala Capital Management, LLC |
13D/G
13F
Company
|
6.5%
|
$23,808,987
4,839,225 shares
|
-$11,238,663 | 31 Mar 2026 |
| Foundation Fighting Blindness Retinal Degeneration Fund |
13D/G
3/4/5
Director, Other*
|
4.7%
|
$17,709,439
3,792,171 shares
|
-$7,939,000 | 18 May 2026 |
| BIOS Fund III, LP |
13D/G
AARON G.L. FLETCHER
|
4.5%
|
$18,122,471
3,683,429 shares
|
$0 | 12 May 2026 |
| Foundation Fighting Blindness, Inc. |
3/4/5
Director, Other*
|
4.7%
|
$16,495,943
3,792,171 shares
|
-$7,395,000 | 18 May 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$23,448,616.
Buys
$323,693
Insiders: 1
Sells
$23,772,309
Insiders: 8
Net
-$23,448,616
Shares: -7,309,395
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 164,000
Shares: 7,473,395
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 3,438,703 | $0 | $14,991,641 | -$14,991,641 |
| 3-6 | 164,000 | 34,692 | $323,693 | $180,668 | +$143,025 |
| 6-9 | 0 | 4,000,000 | $0 | $8,600,000 | -$8,600,000 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to Opus Genetics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
Foundation Fighting Blindness, Inc.
Net 12M change
-$23,448,616
Latest report
18 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Foundation Fighting Blindness, Inc. | Director, Other* | $16,495,943 | -$7,395,000 | -31% | Filing P/S | 18 May 2026 |
| Foundation Fighting Blindness Retinal Degeneration Fund | Director, Other* | $16,495,943 | -$15,995,000 | -49% | Filing P/S | 18 May 2026 |
| Cam Gallagher | Director | $9,549,526 | +$323,693 | +3.5% | Median | 20 Apr 2026 |
| George Magrath | Chief Executive Officer, Director | $9,089,815 | -$176,974 | -1.9% | Filing P/S | 23 Apr 2026 |
| Benjamin R. Yerxa | President, Director | $3,726,379 | -$39,121 | -1% | Filing P/S | 23 Apr 2026 |
| Robert E. Gagnon | Chief Financial Officer | $3,070,102 | -$40,658 | -1.3% | Filing P/S | 23 Apr 2026 |
| Ashwath Jayagopal | Chief Scientific & Dev. Ofc. | $2,643,784 | -$58,202 | -2.2% | Filing P/S | 23 Apr 2026 |
| Richard J. Rodgers | Director | $1,560,750 | Median | 20 Apr 2026 | ||
| Joseph K. Schachle | Chief Operating Officer | $1,545,617 | -$44,044 | -2.8% | Filing P/S | 23 Apr 2026 |
| Sean Ainsworth | Director | $1,463,698 | Median | 20 Apr 2026 | ||
| James S. J. Manuso | Director | $1,443,796 | Median | 20 Apr 2026 | ||
| Jean Bennett | Director | $1,178,536 | Median | 20 Apr 2026 | ||
| Susan Benton | Director | $1,109,717 | Median | 20 Apr 2026 | ||
| Rabourn Amy Zaremba | Head of Fin. Quality Assurance | $981,843 | -$23,310 | -2.3% | Filing P/S | 23 Apr 2026 |
| Adrienne L. Graves | Director | $580,188 | Median | 20 Apr 2026 | ||
| Jay Pepose | Director | $318,508 | Mixed | 11 Jun 2024 | ||
| Ronil A. Patel | Chief Business Officer | $296,181 | Mixed | 10 Jan 2024 | ||
| Nirav S. Jhaveri | Chief Financial Officer | $223,437 | Mixed | 13 Mar 2025 | ||
| Bernhard Hoffmann | SVP of Corp. Dev. | $213,263 | Mixed | 13 Mar 2025 | ||
| Mina Sooch | President and CEO, Director | $163,250 | Mixed | 10 Jan 2023 |
Recent insider transactions for Opus Genetics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | IRD | Common Stock | Sale | -31% | $7,395,000 | $4.35 | -1,700,000 | 3,792,171 | 18 May 2026 | Direct |
| Foundation Fighting Blindness Retinal Degeneration Fund | IRD | Common Stock | Sale | -31% | $7,395,000 | $4.35 | -1,700,000 | 3,792,171 | 18 May 2026 | Direct |
| Benjamin R. Yerxa | IRD | Common Stock | Sale | -1.04% | $39,121 | $5.24 | -7,470 | 711,535 | 23 Apr 2026 | Direct |
| Joseph K. Schachle | IRD | Common Stock | Sale | -1.56% | $24,519 | $5.22 | -4,697 | 296,084 | 23 Apr 2026 | Direct |
| Rabourn Amy Zaremba | IRD | Common Stock | Sale | -0.86% | $8,540 | $5.20 | -1,641 | 188,671 | 23 Apr 2026 | Direct |
| George Magrath | IRD | Common Stock | Sale | -0.54% | $49,647 | $5.22 | -9,511 | 1,741,344 | 23 Apr 2026 | Direct |
| Ashwath Jayagopal | IRD | Common Stock | Sale | -1.46% | $39,156 | $5.19 | -7,542 | 509,233 | 23 Apr 2026 | Direct |
| Robert E. Gagnon | IRD | Common Stock | Sale | -1.31% | $40,658 | $5.18 | -7,842 | 592,158 | 23 Apr 2026 | Direct |
| Richard J. Rodgers | IRD | Common Stock | Award | 7.65% | 24,367 | 343,022 | 20 Apr 2026 | Direct | ||
| James S. J. Manuso | IRD | Common Stock | Award | 8.32% | 24,367 | 317,318 | 20 Apr 2026 | Direct | ||
| Adrienne L. Graves | IRD | Common Stock | Award | 23.6% | 24,367 | 127,514 | 20 Apr 2026 | Direct | ||
| Cam Gallagher | IRD | Common Stock | Award | 1.22% | 24,367 | 2,015,797 | 20 Apr 2026 | Direct | ||
| Susan Benton | IRD | Common Stock | Award | 11.1% | 24,367 | 243,894 | 20 Apr 2026 | Direct | ||
| Jean Bennett | IRD | Common Stock | Award | 10.4% | 24,367 | 259,019 | 20 Apr 2026 | Direct | ||
| Sean Ainsworth | IRD | Common Stock | Award | 8.2% | 24,367 | 321,692 | 20 Apr 2026 | Direct | ||
| Joseph K. Schachle | IRD | Common Stock | Sale | -1.22% | $19,525 | $5.25 | -3,719 | 300,781 | 16 Mar 2026 | Direct |
| Rabourn Amy Zaremba | IRD | Common Stock | Sale | -1.46% | $14,770 | $5.24 | -2,816 | 190,312 | 16 Mar 2026 | Direct |
| George Magrath | IRD | Common Stock | Sale | -1.38% | $127,327 | $5.21 | -24,438 | 1,750,855 | 16 Mar 2026 | Direct |
| Ashwath Jayagopal | IRD | Common Stock | Sale | -0.71% | $19,046 | $5.12 | -3,719 | 516,775 | 16 Mar 2026 | Direct |
| Ashwath Jayagopal | IRD | Common Stock | Tax liability | -1.01% | -5,313 | 520,494 | 12 Feb 2026 | Direct | ||
| Rabourn Amy Zaremba | IRD | Common Stock | Award | 81.1% | 86,500 | 193,128 | 22 Jan 2026 | Direct | ||
| George Magrath | IRD | Common Stock | Award | 37.4% | 483,639 | 1,775,293 | 22 Jan 2026 | Direct | ||
| Ashwath Jayagopal | IRD | Common Stock | Award | 318% | 400,000 | 525,807 | 22 Jan 2026 | Direct | ||
| Robert E. Gagnon | IRD | Common Stock | Award | 200% | 400,000 | 600,000 | 22 Jan 2026 | Direct | ||
| Joseph K. Schachle | IRD | Common Stock | Award | 458.7% | 250,000 | 304,500 | 22 Jan 2026 | Direct | ||
| Benjamin R. Yerxa | IRD | Common Stock | Award | 125.4% | 400,000 | 719,005 | 22 Jan 2026 | Direct | ||
| Rabourn Amy Zaremba | IRD | Common Stock | Tax liability | -3.08% | -3,390 | 106,628 | 18 Jan 2026 | Direct | ||
| Rabourn Amy Zaremba | IRD | Common Stock | Tax liability | -3.47% | -3,950 | 110,018 | 10 Jan 2026 | Direct | ||
| Cam Gallagher | IRD | Common Stock | Award | 3.48% | 67,000 | 1,991,430 | 06 Jan 2026 | Direct | ||
| James S. J. Manuso | IRD | Common Stock | Award | 11.9% | 31,188 | 292,951 | 01 Jan 2026 | Direct | ||
| Adrienne L. Graves | IRD | Common Stock | Award | 29.7% | 23,643 | 103,147 | 01 Jan 2026 | Direct | ||
| Jean Bennett | IRD | Common Stock | Award | 9.89% | 21,127 | 234,652 | 01 Jan 2026 | Direct | ||
| Sean Ainsworth | IRD | Common Stock | Award | 16.7% | 42,507 | 297,325 | 01 Jan 2026 | Direct | ||
| Cam Gallagher | IRD | Common Stock | Award | 1.74% | 33,000 | 1,924,430 | 31 Dec 2025 | Direct | ||
| Cam Gallagher | IRD | Common Stock | Purchase | $163,419 | $1.97 | 83,000 | 83,000 | 29 Dec 2025 | By Garret Gallagher - Custodian UTMA/UGMA | |
| Cam Gallagher | IRD | Common Stock | Purchase | 4.47% | $160,275 | $1.98 | 81,000 | 1,891,430 | 29 Dec 2025 | Direct |
| Foundation Fighting Blindness Retinal Degeneration Fund | IRD | Common Stock | Sale | -42.1% | $8,600,000 | $2.15 | -4,000,000 | 5,492,171 | 09 Dec 2025 | Direct |
| George Magrath | IRD | Common Stock | Tax liability | -2.3% | -30,350 | 1,291,654 | 01 Nov 2025 | Direct | ||
| Benjamin R. Yerxa | IRD | Common Stock | Tax liability | -6.94% | -23,795 | 319,005 | 22 Oct 2025 | Direct | ||
| Robert E. Gagnon | IRD | Common Stock | Award | 200,000 | 200,000 | 10 Sep 2025 | Direct | |||
| Robert E. Gagnon | IRD | Employee Stock Option (right to buy) | Award | 250,000 | 250,000 | 02 Sep 2025 | Direct | |||
| Cam Gallagher | IRD | Common Stock | Award | 92.4% | 869,565 | 1,810,430 | 25 Aug 2025 | Direct | ||
| Sean Ainsworth | IRD | Common Stock | Award | 51.8% | 86,956 | 254,818 | 25 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.